AlphAIalphai — Financial news for AI agents
GlobeNewswireNOV 122 min read$MIST

Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

PDUFA Target Date of December 13, 2025 for CARDAMYST™ ( etripamil ) Nasal Spray in Paroxysmal Supraventricular Tachycardia ...

Original reporting
GlobeNewswire · Milestone Pharmaceuticals Inc.
Published Nov 12, 2025, 12:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 12, 2025, 1:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update — source image
Source · www.globenewswire.com
Decision brief

The 30-second read

$MISTBullishHigh
01

Why it matters

Approval could lead to significant stock appreciation; rejection may cause declines.

02

Market read

High relevance for biotech investors and traders focusing on FDA approvals.

03

What to watch

Potential delays or adverse outcomes could negatively impact stock; broader market conditions may also influence price movements.

Timing: Immediate, as the PDUFA date is December 13, 2025.

Background

Milestone Pharmaceuticals is developing CARDAMYST™, a nasal spray for paroxysmal supraventricular tachycardia, with a PDUFA date set for December 13, 2025.

Company-level read

Ticker impact

$MISTBullishHigh confidence
Context

The news pertains to Milestone Pharmaceuticals and its upcoming regulatory milestone, which could influence its stock price.

Expected impact

Potential short-term increase in stock price leading up to December 13, 2025, if market perceives approval as likely.

Evidence & confidence

The upcoming PDUFA target date is a significant catalyst for biotech stocks, especially when approval is anticipated.

Market effects

Sector

Potential positive impact on biotech and pharmaceutical sectors.

Regional

Primarily US-focused due to FDA regulatory process.

Global

Limited, unless approval significantly alters market expectations for similar drugs.

Counterpoint

What could challenge this read

Regulatory approval is uncertain; market may have already priced in the event, leading to limited upside.

Key entities

  • Company
    Milestone Pharmaceuticals Inc.

    Biotech company focused on developing therapies for cardiac arrhythmias.

Read at source← All news

Related articles

AUG 12
$MISTMedAI 8/10

Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Milestone Pharmaceuticals (Nasdaq: MIST) reported Q2 2026 results and a corporate update. It said CARDAMYST (etripamil) prescriptions and coverage expanded, with cash, cash equivalents and short-term investments of $170.6 million as of June 30, 2026. The Phase 3 ReVeRA-301 AFib-RVR trial opened, and EMA/China reviews are ongoing. Q2 net loss was $28.6 million.

finanznachrichten.de7 min
AUG 12
$MISTMed

Milestone Pharmaceuticals Inc. (MIST): Results of Operations and Financial Condition

Milestone Pharmaceuticals Inc. (MIST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2614433d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage

SEC EDGAR 8-K6 min
AUG 12
$VBIOMed

Valion Bio, Inc.: Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury

Valion Bio (Nasdaq:VBIO) said AFRRI, under a contract with NIAID, is running U.S. government-funded studies of Entolimod for radiation-induced GI injury. A safety study is planned to start this week, followed by a therapeutic study with top-line data expected in early fall. The program aims to assess survival and GI recovery after lethal radiation doses.

finanznachrichten.de4 min
AUG 12
$STTKMed

H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion

H.C. Wainwright cut its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18 while keeping a Buy rating, after Shattuck reported Q2 2026 results on Aug. 11. Shattuck expanded its RECEPTIVE-CD1 Phase 2b trial to three doses and ~232 patients. The SL-325 Crohn’s trial remains on track for a Q3 2026 start. The article also notes a $75M public offering and warrant exercises.

investing.com4 min
AUG 12
$FGLMed

Founder Group Limited Secures Second Aquaculture Contract, a US$1.4 million 1.78 MW rooftop system for a Kedah shrimp Farm

Founder Group Limited (NASDAQ: FGL) said its subsidiary Founder Energy Sdn Bhd signed a turn-key EPCC contract for a 1.78 MW-peak rooftop solar system for a shrimp farming and processing facility in Ayer Hitam, Kedah. The contract is valued at about RM5.58 million (US$1.37 million). The company also cited Malaysia RE policy targets and plans for 25-year operations.

thestarphoenix.com4 min
AUG 12
$AEHRMed

Aehr Test Systems: Aehr Receives $22 Million Follow-On Order for AI Processor Wafer-Level Burn-In Systems

Aehr Test Systems (NASDAQ:AEHR) said it received a $22 million follow-on production order from its lead wafer-level AI processor customer. The order includes multiple FOX-XP wafer-level burn-in systems plus FOX WaferPak contactors and auto aligners, testing nine 300mm wafers per system. Aehr expects shipment over six months for installation in Taiwan.

finanznachrichten.de4 min